Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
View abstract on PubMed
Summary
This summary is machine-generated.High-quality neoantigens, not just quantity, predict long-term survival in pancreatic cancer. These specific T-cell targets, including those from MUC16, offer new avenues for immunotherapy in pancreatic ductal adenocarcinoma.
Area Of Science
- Oncology
- Immunology
- Computational Biology
Background
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with T-cell immunity implicated in rare long-term survival cases.
- Identifying specific T-cell antigens driving this immunity is crucial for therapeutic development.
Purpose Of The Study
- To identify T-cell antigens and their qualities associated with long-term survival in pancreatic cancer.
- To evaluate neoantigen quantity versus quality as predictors of patient outcomes and T-cell responses.
Main Methods
- Whole-exome sequencing and in silico neoantigen prediction.
- Immunohistochemical and transcriptional immunoprofiling.
- Computational biophysics and functional T-cell assays.
Main Results
- Tumor neoantigen load and CD8+ T-cell infiltrates together, but not alone, stratified long-term survivors.
- A neoantigen quality fitness model, emphasizing differential presentation and microbial homology, identified survivors, unlike a quantity-based model.
- Long-term survivors showed T-cell reactivity to high-quality and MUC16 neoantigens, with evidence of molecular mimicry and neoantigen loss during metastasis.
Conclusions
- Neoantigen quality, particularly involving MUC16 and features of immunogenicity, is a key determinant of T-cell responses and survival in PDAC.
- Neoantigen quality serves as a biomarker for immunogenic tumors, potentially guiding immunotherapy strategies.
- Understanding neoantigen characteristics is vital for developing effective immunotherapies for pancreatic cancer.